Search Result

Results for "

Tumor uptake

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (1) Apoptosis (2) Autophagy (1) CXCR (1) Drug Metabolite (1) Drug-Linker Conjugates for ADC (1) Endogenous Metabolite (2) FAP (2) Fluorescent Dye (1) GLUT (1) HIV (1) Notch (1) PSMA (3) Sigma Receptor (1) Somatostatin Receptor (2)
By Research Areas:	Cancer (25) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (1) Metabolic Disease (3) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P5126

DOTA-LM3	Somatostatin Receptor	Cancer
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis .

HY-P5126A

DOTA-LM3 TFA	Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis .

HY-137331

FAPI-46 1 Publications Verification	FAP	Cancer
FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation. FAPI-46 can be used for tumor imaging of a multitude of different cancers .

HY-D2281

[99mTc]Tc-6–1	FAP	Cancer
[99m Tc]Tc-6-1, a ^99mTc-labeled FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted radiotracer. [99m Tc]Tc-6-1 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

HY-161699

SDTWS01	PSMA	Cancer
SDTWS01 is a novel 68Ga-labeled prostate-specific membrane antigen (PSMA) targeting tracer. The inhibition constant (K_i) of SDTWS01 for PSMA is in the nanomolar range (less than 10 nM), demonstrating high affinity for PSMA. SDTWS01 exhibits significant tumor uptake and superior PET imaging effects. SDTWS01 can be utilized for diagnostic research of prostate cancer .

HY-163683

EB-PSMA-617	Drug-Linker Conjugates for ADC	Cancer
EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity .

HY-123733A

MIP-1095 TFA RPS-001 TFA	PSMA	Cancer
MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled ( ¹³¹I labeled) as an imaging probe to indicate tumor progression. And ¹³¹I-MIP-1095 showed higher renal uptake in mice .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

HY-158266

DOTA-PSMA-EB-01 LNC1003	PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors .

HY-156124

Sigma-2 Radioligand 1	Sigma Receptor	Cancer
Sigma-2 Radioligand 1 (compound 1) is a Sigma-2 selective ligand. Sigma-2 Radioligand 1 has good biodistribution in mice and good in vivo activity in rats. [18F] Modified Sigma-2 Radioligand 1 for visualization of tumors in micro-PET/CT imaging, exhibiting high tumor uptake and tumor-to-background ratio. Experiments show that Sigma-2 Radioligand 1 binds highly specifically in U87MG glioma xenografts .

HY-143618

photoCORM-2	Others	Cancer
photoCORM-2 (compound 3) is a single carbon monoxide releasing molecule (CORM). photoCORM-2 exhibits good cellular uptake and real-time monitoring ability of CO uncaging by a color change approach. photoCORM-2 has anti-tumor activity .

HY-143617

photoCORM-1	Others	Cancer
photoCORM-1 (compound 8) is a combinatorial carbon monoxide releasing molecule (CORM). photoCORM-1 exhibits good cellular uptake and real-time monitoring ability of CO uncaging by a color change approach. photoCORM-1 has anti-tumor antivity .

HY-156594

Abefolastat tesaroxetan SarbisPSMA	Others	Cancer
Abefolastat tesaroxetan (SarbisPSMA) is a bivalent sarcophagine conjugate. Abefolastat tesaroxetan (SarbisPSMA) can be readily radiolabeled with positron-emitting copper-64 at room temperature and outperforms the monomeric agent with respect to tumor uptake and retention. Abefolastat tesaroxetan (SarbisPSMA) can be used for prostate cancer research .

HY-17026E

Gemcitabine triphosphate trisodium dFdCTP trisodium	Endogenous Metabolite	Cancer
Gemcitabine triphosphate (trisodium) is one of the two nucleoside metabolites of Gemcitabine (HY-17026) in cells. The other is active diphosphate (dFdDTP). Gemcitabine triphosphate can be used as a standard in radio-labeled probe imaging studies, to identify tumors sensitive to Gemcitabine, and to evaluate Gemcitabine uptake and retention by cells .

HY-17026A

Gemcitabine triphosphate dFdCTP	Drug Metabolite Endogenous Metabolite	Cancer
Gemcitabine triphosphate (dFdCTP) is one of the two nucleoside metabolites of Gemcitabine (HY-17026) in cells. The other is active diphosphate (dFdDTP). Gemcitabine triphosphate can be used as a standard in radio-labeled probe imaging studies, to identify tumors sensitive to Gemcitabine, and to evaluate Gemcitabine uptake and retention by cells .

HY-101849

Fasentin 4 Publications Verification	GLUT TNF Receptor Apoptosis	Cardiovascular Disease Cancer
Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC₅₀=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .

HY-12203

PFK-158 Maximum Cited Publications 7 Publications Verification	Autophagy Apoptosis	Cancer
PFK-158 is a potent and selective PFKFB3 inhibitor with an IC₅₀ value 137 nM. PFK-158 reduces glucose uptake, ATP production, lactate release, and induces apoptosis and autophagy in cancer cells. PFK-158 has broad anti-tumor activity. PFK-158 can also enhance Colistin's resistance to bacteria .

HY-148114

MOPIPP	Others	Cancer
MOPIPP is a novel indolebased chalcone, and vacuolin-1, is a non-lethal vacuoleinducing 2-propyl analog of MOMIPP (HY-148114). MOPIPP induces cellular vacuolization and increases autophagosomes numbers. MOPIPP also triggers methuosis, and interrupts glucose uptake and glycolytic metabolism. MOPIPP can cross the blood-brain barrier and shows efficacy in suppressing tumor progression agaisnt glioblastoma cells .

HY-163281

FSY-OSO2F	Fluorescent Dye	Cancer
FSY-OSO2F is used as an amino acid tracer for subsutaneous MCF-7 tumors after labeling with isotope ¹⁸F. FSY-OSO2F shows an uptake in MCF-7 cells through the regulation of L-Tyr, ASC, and ASC2 transporters. FSY-OSO2F visualizes the U78MG glioma labeled with ¹⁸F .

HY-B1231

Heptaminol hydrochloride RP-2831 hydrochloride	Others	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Heptaminol (RP-2831) hydrochloride is a vasoconstrictor used in the study of hypotension, especially orthostatic hypotension. Heptaminol is also a skin cancer proliferation inhibitor that inhibits immune inflammation induced by the tumor promoting factor 12-O-tetradecanoylphorbol-13-acetate (TPA) in an NO-dependent manner. Heptaminol also acts as a sympathomimetic amine, exerting indirect sympathetic effects. Heptaminol is also an antagonist of catecholamine release and uptake and can increase intracellular free calcium levels .

HY-N6924

Zingibroside R1	HIV	Infection Metabolic Disease
Zingibroside R1 is dammaranae-type triterpenoid saponin, isolated from rhizomes, taproots, and lateral roots of Panax japonicas C. A. Meyer, shows excellent anti-tumor effects as well as anti-angiogenic activity . Zingibroside R1 possesses some anti-HIV-1 activity. Zingibroside R1 has inhibitory effects on the 2-deoxy-D-glucose (2-DG) uptake by EAT cells (IC₅₀=91.3 μM) .

HY-P10444

DOTA Conjugated JM#21 derivative 7	CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney .

HY-W010713

Meso-tetraphenylchlorin Fimaporfin free base	Others	Cancer
Meso-tetraphenylchlorin (TPCS2a) is a photosensitizer with poor water solubility, which limits its use in the blood circulation. However, TPCS2a@NPs nanoparticles can be prepared based on polylactic-co-polyethylene glycol acid (PLGA) polymer core loaded with TPCS2. Such nanoparticles can be coated with mesenchymal stem cell-derived plasma membranes (mMSCs) to form mMSC-TPCS2a@NPs, which prolongs blood circulation time and improves tumor targeting ability. Compared with uncoated TPCS2a@NPs, mMSC-TPCS2a@NPs can reduce macrophage uptake by 54% to 70% under different conditions. Both nanoparticle forms are effectively accumulated in MCF7 and MDA-MB-231 breast cancer cells, while uptake in normal breast epithelial cells MCF10A is significantly lower .

HY-124689

TR-100	Others	Metabolic Disease Cancer
TR-100 is a small molecule inhibitor of tumor-associated troponin (Tpm). TR-100 affects the interaction of Tpm3.1 with actin filaments by binding to the C-terminal of Tpm3.1, thereby affecting the stability and function of the actin filaments. This mechanism of action allows TR-100 to specifically affect actin filaments in cancer cells without compromising heart muscle function. TR-100 can be used to study the role of Tpm3.1 in cancer cell proliferation and survival and the effects of Tpm3.1 on insulin-stimulated glucose uptake and insulin secretion .

Cat. No.	Product Name

HY-L083

Anti-Cancer Metabolism Compound Library	2,095 compounds
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth. MCE provides a unique collection of 2,095 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Anti-Cancer Metabolism Compound Library

2,095 compounds

Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth.

MCE provides a unique collection of 2,095 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Cat. No.	Product Name	Type